Related references
Note: Only part of the references are listed.Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer
Megan L. Kruse et al.
JCI INSIGHT (2021)
Germline HSD3B1 Genetics and Prostate Cancer Outcomes
Lewis Thomas et al.
UROLOGY (2020)
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer
Jason W. D. Hearn et al.
JAMA ONCOLOGY (2018)
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer
Nima Almassi et al.
JAMA ONCOLOGY (2018)
Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers
Kristy A. Brown et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status
Yuan-Ching Chang et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer
Lu Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
Jason W. D. Hearn et al.
LANCET ONCOLOGY (2016)
Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations
Toru Hanamura et al.
CANCER MEDICINE (2016)
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
Betsy A. Kohler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Relationships of sex steroid hormone levels in benign and cancerous breast tissue and blood: A critical appraisal of current science
Frank Z. Stanczyk et al.
STEROIDS (2015)
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
Betsy A. Kohler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Mechanisms of aromatase inhibitor resistance
Cynthia X. Ma et al.
NATURE REVIEWS CANCER (2015)
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism
Toru Hanamura et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
T. E. Hickey et al.
MOLECULAR ENDOCRINOLOGY (2012)
The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
Matthew J. Sikora et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Mechanisms of disease: Estrogen carcinogenesis in breast cancer
JD Yager et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Endocrine and intracrine sources of androgens in women:: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone
F Labrie et al.
ENDOCRINE REVIEWS (2003)